Magnesium in the treatment of alcohol withdrawal syndrome: a multicenter randomized controlled trial
- 3 April 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in Alcohol and Alcoholism
- Vol. 58 (3) , 329-335
Abstract
Alcohol withdrawal syndrome (AWS) is a frequent and potentially life-threatening condition experienced in alcohol use disorder. Since hypomagnesemia is involved in AWS’s severity, we conducted a multicenter double-blind randomized placebo-controlled trial to examine the efficacy of oral magnesium supplementation as an adjuvant therapy of AWS. Inpatients were recruited in six different centers if they had a baseline score higher than eight on the Revised Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar). The experimental treatment was magnesium lactate dehydrate, administrated three times per day providing a total of 426.6 mg per day and up to 15 days. The primary endpoint was the significant between-group difference of the CIWA-Ar total score change from baseline to 3 days later. The treatment group and baseline score were introduced as covariables in an analysis of covariance. A total of 98 inpatients were included {71.4% of men; mean age of 49.1 years [standard deviation (SD): 10.3]}. In the intention-to-treat population, the mean reduction of the CIWA-Ar score in the experimental group between baseline and 3 days later was 10.1 (SD: 5.2), whereas it was 9.2 (SD: 3.9) in the control group. The absolute difference of the adjusted mean in the experimental group compared with the control group was −0.69 (SD: 0.72), which did not correspond to a significant between-group difference (P = 0.34). Per-protocol analysis and sensitivity analyses also supported this result. Supplementary analyses found no significant difference regarding benzodiazepine consumption, magnesium blood concentration, and satisfaction to care. The present study does not support the rationale of systematic oral magnesium supplementation in patients with AWS.Keywords
Funding Information
- French national PHRC
This publication has 34 references indexed in Scilit:
- A double blind randomised comparison of chlordiazepoxide and lorazepam in alcohol withdrawalAsian Journal of Psychiatry, 2013
- Benzodiazepines: Risks and benefits. A reconsiderationJournal of Psychopharmacology, 2013
- Magnesium basicsClinical Kidney Journal, 2012
- Glutamatergic hyperfunctioning during alcohol withdrawal syndrome: Therapeutic perspective with zinc and magnesiumMedical Hypotheses, 2011
- How usual is usual care in pragmatic intervention studies in primary care? An overview of recent trialsBritish Journal of General Practice, 2010
- Delayed restoration of Mg2+content and transport in liver cells following ethanol withdrawalAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2009
- A multi-centre survey of inpatient pharmacological management strategies for alcohol withdrawalQJM: An International Journal of Medicine, 2009
- Magnesium treatment in alcoholics: A randomized clinical trialSubstance Abuse Treatment, Prevention, and Policy, 2008
- Consequences of magnesium deficiency on the enhancement of stress reactions; preventive and therapeutic implications (a review).Journal of the American College of Nutrition, 1994
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987